Refining the Management of Advanced Melanoma

Refining the Management of Advanced Melanoma

Episodes

Specialty:

All

Year:

All

EP. 1: Recommendations for Resectability in Melanoma

July 5th 2017

EP. 2: Adjuvant Therapy for Patients with Melanoma

July 5th 2017

EP. 3: Emerging Adjuvant and Neoadjuvant Options for Melanoma

July 5th 2017

EP. 4: Dual Targeted or Immunotherapy for BRAF-Mutant Melanoma

July 5th 2017

EP. 5: Options for NRAS-Mutant Melanoma

July 5th 2017

EP. 6: How Are You using PD-1 Testing in Melanoma?

July 5th 2017

EP. 7: Long-Term Results for Immunotherapy in Melanoma

July 5th 2017

EP. 8: New Data for Immunotherapy in Melanoma Brain Metastases

July 5th 2017

EP. 9: Oncolytic Immunotherapy in Metastatic Melanoma

July 5th 2017

EP. 10: Optimal Treatment of Metastatic Melanoma at Progression

July 5th 2017

EP. 11: Novel Combinations for Metastatic Melanoma

July 5th 2017

EP. 12: IDO Inhibitors in Metastatic Melanoma

July 5th 2017

EP. 13: Novel Targeted Therapies for Metastatic Melanoma

July 5th 2017

EP. 14: Metastatic Melanoma: Clinical Pearls From the Experts

July 5th 2017

Trending on OncLive

CLL Treatment Individualization Prompts Changes in Patient Evaluation and Care

Japan Approves Subcutaneous Pembrolizumab for All Approved Pembrolizumab Indications

FDA Grants Fast Track Designation to LYT-200 in R/R High-Risk MDS

Integrating Bispecific Antibodies Into Frontline Therapy for Newly Diagnosed Multiple Myeloma

NAPISTAR-1-01 Data Support Rapid TUB-040 Development in Biomarker-Unrestricted Ovarian Cancer